|
1
|
Taurog JD, Chhabra A and Colbert RA:
Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med.
374:2563–2574. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Brewerton DA, Hart FD, Nicholls A, Caffrey
M, James DC and Sturrock RD: Ankylosing spondylitis and HL-A 27.
Lancet. 1:904–907. 1973.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Brown MA, Kennedy LG, MacGregor AJ, Darke
C, Duncan E, Shatford JL, Taylor A, Calin A and Wordsworth P:
Susceptibility to ankylosing spondylitis in twins: The role of
genes, HLA, and the environment. Arthritis Rheum. 40:1823–1828.
1997.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Manasson J, Shen N, Garcia Ferrer HR,
Ubeda C, Iraheta I, Heguy A, Von Feldt JM, Espinoza LR, Garcia
Kutzbach A, Segal LN, et al: Gut microbiota perturbations in
reactive arthritis and postinfectious spondyloarthritis. Arthritis
Rheumatol. 70:242–254. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhang Y, Guerassimov A, Leroux JY, Cartman
A, Webber C, Lalic R, de Miguel E, Rosenberg LC and Poole AR:
Arthritis induced by proteoglycan aggrecan G1 domain in BALB/c
mice. Evidence for t cell involvement and the immunosuppressive
influence of keratan sulfate on recognition of t and b cell
epitopes. J Clin Invest. 101:1678–1686. 1998.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Capkova J, Hrncir T, Kubatova A and
Tlaskalova-Hogenova H: Lipopolysaccharide treatment suppresses
spontaneously developing ankylosing enthesopathy in B10.BR male
mice: The potential role of interleukin-10. BMC Musculoskelet
Disord. 13(110)2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Thjodleifsson B, Geirsson AJ, Björnsson S
and Bjarnason I: A common genetic background for inflammatory bowel
disease and ankylosing spondylitis: A genealogic study in Iceland.
Arthritis Rheum. 56:2633–2639. 2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Robinson PC, Leo PJ, Pointon JJ, Harris J,
Cremin K, Bradbury LA, Stebbings S and Harrison AA: Australian
Osteoporosis Genetics Consortium; Wellcome Trust Case Control
Consortium et al. Exome-wide study of ankylosing spondylitis
demonstrates additional shared genetic background with inflammatory
bowel disease. NPJ Genom Med. 1(16008)2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tsui FW, Tsui HW, Akram A, Haroon N and
Inman RD: The genetic basis of ankylosing spondylitis: New insights
into disease pathogenesis. Appl Clin Genet. 7:105–115.
2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Costello ME, Ciccia F, Willner D,
Warrington N, Robinson PC, Gardiner B, Marshall M, Kenna TJ, Triolo
G and Brown MA: Brief report: Intestinal dysbiosis in ankylosing
spondylitis. Arthritis Rheumatol. 67:686–691. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Taurog JD, Richardson JA, Croft JT,
Simmons WA, Zhou M, Fernández-Sueiro JL, Balish E and Hammer RE:
The germfree state prevents development of gut and joint
inflammatory disease in HLA-B27 transgenic rats. J Exp Med.
180:2359–2364. 1994.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Asquith MJ, Stauffer P, Davin S, Mitchell
C, Lin P and Rosenbaum JT: Perturbed mucosal immunity and dysbiosis
accompany clinical disease in a rat model of spondyloarthritis.
Arthritis Rheumatol. 68:2151–2162. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lin P, Bach M, Asquith M, Lee AY,
Akileswaran L, Stauffer P, Davin S, Pan Y, Cambronne ED, Dorris M,
et al: HLA-B27 and human β2-microglobulin affect the gut microbiota
of transgenic rats. PLoS One. 9(e105684)2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhang L, Hu Y, Xu Y, Li P, Ma H, Li X and
Li M: The correlation between intestinal dysbiosis and the
development of ankylosing spondylitis. Microb Pathog. 132:188–192.
2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Turner MJ, Sowders DP, DeLay ML, Mohapatra
R, Bai S, Smith JA, Brandewie JR, Taurog JD and Colbert RA: HLA-B27
misfolding in transgenic rats is associated with activation of the
unfolded protein response. J Immunol. 175:2438–2448.
2005.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kaneko M and Nomura Y: ER signaling in
unfolded protein response. Life Sci. 74:199–205. 2003.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ciccia F, Accardo-Palumbo A, Rizzo A,
Guggino G, Raimondo S, Giardina A, Cannizzaro A, Colbert RA,
Alessandro R and Triolo G: Evidence that autophagy, but not the
unfolded protein response, regulates the expression of IL-23 in the
gut of patients with ankylosing spondylitis and subclinical gut
inflammation. Ann Rheum Dis. 73:1566–1574. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ciccia F, Rizzo A and Triolo G:
Subclinical gut inflammation in ankylosing spondylitis. Curr Opin
Rheumatol. 28:89–96. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tian P, Li B, He C, Song W, Hou A, Tian S,
Meng X, Li K and Shan Y: Antidiabetic (type 2) effects of
Lactobacillus G15 and Q14 in rats through regulation of
intestinal permeability and microbiota. Food Funct. 7:3789–3797.
2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Morris G, Berk M, Carvalho AF, Caso JR,
Sanz Y and Maes M: The role of microbiota and intestinal
permeability in the pathophysiology of autoimmune and neuroimmune
processes with an emphasis on inflammatory bowel disease type 1
diabetes and chronic fatigue syndrome. Curr Pharm Des.
22:6058–6075. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ebringer A and Wilson C: The use of a low
starch diet in the treatment of patients suffering from ankylosing
spondylitis. Clin Rheumatol. 15 (Suppl 1):S62–S66. 1996.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ugur M, Baygutalp NK, Melikoglu MA,
Baygutalp F, Altas EU and Seferoglu B: Elevated serum
interleukin-23 levels in ankylosing spondylitis patients and the
relationship with disease activity. Nagoya J Med Sci. 77:621–627.
2015.PubMed/NCBI
|
|
23
|
Smith JA and Colbert RA: Review: The
interleukin-23/interleukin-17 axis in spondyloarthritis
pathogenesis: Th17 and beyond. Arthritis Rheumatol. 66:231–241.
2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ciccia F, Guggino G, Rizzo A, Saieva L,
Peralta S, Giardina A, Cannizzaro A, Sireci G, De Leo G, Alessandro
R and Triolo G: Type 3 innate lymphoid cells producing IL-17 and
IL-22 are expanded in the gut, in the peripheral blood, synovial
fluid and bone marrow of patients with ankylosing spondylitis. Ann
Rheum Dis. 74:1739–1747. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Costello ME, Elewaut D, Kenna TJ and Brown
MA: Microbes, the gut and ankylosing spondylitis. Arthritis Res
Ther. 15(214)2013.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
van der Linden S, Valkenburg HA and Cats
A: Evaluation of diagnostic criteria for ankylosing spondylitis. A
proposal for modification of the New York criteria. Arthritis
Rheum. 27:361–368. 1984.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang W, Chen L, Zhou R, Wang X, Song L,
Huang S, Wang G and Xia B: Increased proportions of
Bifidobacterium and the Lactobacillus group and loss
of butyrate-producing bacteria in inflammatory bowel disease. J
Clin Microbiol. 52:398–406. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhang L, Han R, Zhang X, Fang G, Chen J,
Li J, Xu S, Qian L, Chen W and Pan F: Fecal microbiota in patients
with ankylosing spondylitis: Correlation with dietary factors and
disease activity. Clin Chim Acta. 497:189–196. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Breban M, Tap J, Leboime A, Said-Nahal R,
Langella P, Chiocchia G, Furet JP and Sokol H: Faecal microbiota
study reveals specific dysbiosis in spondyloarthritis. Ann Rheum
Dis. 76:1614–1622. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Morgan XC, Tickle TL, Sokol H, Gevers D,
Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, et
al: Dysfunction of the intestinal microbiome in inflammatory bowel
disease and treatment. Genome Biol. 13(R79)2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Scher JU, Ubeda C, Artacho A, Attur M,
Isaac S, Reddy SM, Marmon S, Neimann A, Brusca S, Patel T, et al:
Decreased bacterial diversity characterizes the altered gut
microbiota in patients with psoriatic arthritis, resembling
dysbiosis in inflammatory bowel disease. Arthritis Rheumatol.
67:128–139. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tito RY, Cypers H, Joossens M, Varkas G,
Van Praet L, Glorieus E, Van den Bosch F, De Vos M, Raes J and
Elewaut D: Brief report: Dialister as a microbial marker of disease
activity in spondyloarthritis. Arthritis Rheumatol. 69:114–121.
2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Haque TR and Barritt AS IV: Intestinal
microbiota in liver disease. Best Pract Res Clin Gastroenterol.
30:133–142. 2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Minemura M and Shimizu Y: Gut microbiota
and liver diseases. World J Gastroenterol. 21:1691–1702.
2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Morris A: Metabolism: New insights into
the BAT-liver-gut axis. Nat Rev Endocrinol. 13(438)2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Yip LY, Aw CC, Lee SH, Hong YS, Ku HC, Xu
WH, Chan JMX, Cheong EJY, Chng KR, Ng AHQ, et al: The liver-gut
microbiota axis modulates hepatotoxicity of tacrine in the rat.
Hepatology. 67:282–295. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Pallen MJ and Quraishi MN: The gut
microbiota and the hepatologist: Will our bugs prove to be the
missing link? Dig Dis. 35:377–383. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Rabb H, Pluznick J and Noel S: The
microbiome and acute kidney injury. Nephron. 140:120–123.
2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Noel S, Martina-Lingua MN, Bandapalle S,
Pluznick J, Hamad AR, Peterson DA and Rabb H: Intestinal
microbiota-kidney cross talk in acute kidney injury and chronic
kidney disease. Nephron Clin Pract. 127:139–143. 2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Sabatino A, Regolisti G, Brusasco I,
Cabassi A, Morabito S and Fiaccadori E: Alterations of intestinal
barrier and microbiota in chronic kidney disease. Nephrol Dial
Transplant. 30:924–933. 2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Ostan R, Béné MC, Spazzafumo L, Pinto A,
Donini LM, Pryen F, Charrouf Z, Valentini L, Lochs H,
Bourdel-Marchasson I, et al: Impact of diet and nutraceutical
supplementation on inflammation in elderly people. Results from the
RISTOMED study, an open-label randomized control trial. Clin Nutr.
35:812–818. 2016.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Valentini L, Pinto A, Bourdel-Marchasson
I, Ostan R, Brigidi P, Turroni S, Hrelia S, Hrelia P, Bereswill S,
Fischer A, et al: Impact of personalized diet and probiotic
supplementation on inflammation, nutritional parameters and
intestinal microbiota-The ‘RISTOMED project’: Randomized controlled
trial in healthy older people. Clin Nutr. 34:593–602.
2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Klingberg E, Magnusson MK, Strid H,
Deminger A, Ståhl A, Sundin J, Simrén M, Carlsten H, Öhman L and
Forsblad-d'Elia H: A distinct gut microbiota composition in
patients with ankylosing spondylitis is associated with increased
levels of fecal calprotectin. Arthritis Res Ther.
21(248)2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Rizzatti G, Lopetuso LR, Gibiino G, Binda
C and Gasbarrini A: Proteobacteria: A common factor in human
diseases. Biomed Res Int. 2017(9351507)2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
McIlroy J, Ianiro G, Mukhopadhya I, Hansen
R and Hold GL: Review article: The gut microbiome in inflammatory
bowel disease-avenues for microbial management. Aliment Pharmacol
Ther. 47:26–42. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Ciccia F, Guggino G, Rizzo A, Alessandro
R, Luchetti MM, Milling S, Saieva L, Cypers H, Stampone T, Di
Benedetto P, et al: Dysbiosis and zonulin upregulation alter gut
epithelial and vascular barriers in patients with ankylosing
spondylitis. Ann Rheum Dis. 76:1123–1132. 2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Klingberg E, Strid H, Ståhl A, Deminger A,
Carlsten H, Öhman L and Forsblad-d'Elia H: A longitudinal study of
fecal calprotectin and the development of inflammatory bowel
disease in ankylosing spondylitis. Arthritis Res Ther.
19(21)2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Van Praet L, Jans L, Carron P, Jacques P,
Glorieus E, Colman R, Cypers H, Mielants H, De Vos M, Cuvelier C,
et al: Degree of bone marrow oedema in sacroiliac joints of
patients with axial spondyloarthritis is linked to gut inflammation
and male sex: Results from the GIANT cohort. Ann Rheum Dis.
73:1186–1189. 2014.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Onderdonk AB, Richardson JA, Hammer RE and
Taurog JD: Correlation of cecal microflora of HLA-B27 transgenic
rats with inflammatory bowel disease. Infect Immun. 66:6022–6023.
1998.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Aron-Wisnewsky J, Prifti E, Belda E, Ichou
F, Kayser BD, Dao MC, Verger EO, Hedjazi L, Bouillot JL, Chevallier
JM, et al: Major microbiota dysbiosis in severe obesity: Fate after
bariatric surgery. Gut. 68:70–82. 2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Ley RE, Turnbaugh PJ, Klein S and Gordon
JI: Microbial ecology: Human gut microbes associated with obesity.
Nature. 444:1022–1023. 2006.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ley RE, Bäckhed F, Turnbaugh P, Lozupone
CA, Knight RD and Gordon JI: Obesity alters gut microbial ecology.
Proc Natl Acad Sci USA. 102:11070–11075. 2005.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Kasai C, Sugimoto K, Moritani I, Tanaka J,
Oya Y, Inoue H, Tameda M, Shiraki K, Ito M, Takei Y and Takase K:
Comparison of the gut microbiota composition between obese and
non-obese individuals in a Japanese population, as analyzed by
terminal restriction fragment length polymorphism and
next-generation sequencing. BMC Gastroenterol.
15(100)2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Angelakis E, Armougom F, Carrière F,
Bachar D, Laugier R, Lagier JC, Robert C, Michelle C, Henrissat B
and Raoult D: A metagenomic investigation of the duodenal
microbiota reveals links with obesity. PLoS One.
10(e0137784)2015.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Hu HJ, Park SG, Jang HB, Choi MK, Park KH,
Kang JH, Park SI, Lee HJ and Cho SH: Obesity alters the microbial
community profile in Korean adolescents. PLoS One.
10(e0134333)2015.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Parkes GC, Whelan K and Lindsay JO:
Smoking in inflammatory bowel disease: Impact on disease course and
insights into the aetiology of its effect. J Crohn's Colitis.
8:717–725. 2014.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Savin Z, Kivity S, Yonath H and Yehuda S:
Smoking and the intestinal microbiome. Arch Microbiol. 200:677–684.
2018.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Chen Z, Qi J, Wei Q, Zheng X, Wu X, Li X,
Liao Z, Lin Z and Gu J: Variations in gut microbial profiles in
ankylosing spondylitis: Disease phenotype-related dysbiosis. Ann
Transl Med. 7(571)2019.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Kolho KL, Korpela K, Jaakkola T, Pichai
MV, Zoetendal EG, Salonen A and de Vos WM: Fecal microbiota in
pediatric inflammatory bowel disease and its relation to
inflammation. Am J Gastroenterol. 110:921–930. 2015.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Wallace JL: NSAID gastropathy and
enteropathy: Distinct pathogenesis likely necessitates distinct
prevention strategies. Br J Pharmacol. 165:67–74. 2012.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Wallace JL: Mechanisms, prevention and
clinical implications of nonsteroidal anti-inflammatory
drug-enteropathy. World J Gastroenterol. 19:1861–1876.
2013.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Montrose DC, Zhou XK, McNally EM, Sue E,
Yantiss RK, Gross SS, Leve ND, Karoly ED, Suen CS, Ling L, et al:
Celecoxib alters the intestinal microbiota and metabolome in
association with reducing polyp burden. Cancer Prev Res (Phila).
9:721–731. 2016.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Montenegro L, Losurdo G, Licinio R,
Zamparella M, Giorgio F, Ierardi E, Di Leo A and Principi M: Non
steroidal anti-inflammatory drug induced damage on lower
gastro-intestinal tract: Is there an involvement of microbiota?
Curr Drug Saf. 9:196–204. 2014.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Danese S, Sans M, Scaldaferri F, Sgambato
A, Rutella S, Cittadini A, Piqué JM, Panes J, Katz JA, Gasbarrini A
and Fiocchi C: TNF-alpha blockade down-regulates the CD40/CD40L
pathway in the mucosal microcirculation: A novel anti-inflammatory
mechanism of infliximab in Crohn's disease. J Immunol.
176:2617–2624. 2006.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Yin J, Sternes PR, Wang M, Song J,
Morrison M, Li T, Zhou L, Wu X, He F, Zhu J, et al: Shotgun
metagenomics reveals an enrichment of potentially cross-reactive
bacterial epitopes in ankylosing spondylitis patients, as well as
the effects of TNFi therapy upon microbiome composition. Ann Rheum
Dis. 79:132–140. 2020.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Liu B, Yang L, Cui Z, Zheng J, Huang J,
Zhao Q, Su Z, Wang M, Zhang W, Liu J, et al: Anti-TNF-α therapy
alters the gut microbiota in proteoglycan-induced ankylosing
spondylitis in mice. Microbiologyopen. 8(e927)2019.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Zhang F, Ma C and Zhang B: Dynamic
variations in gut microbiota in ankylosing spondylitis patients
treated with anti-TNF-α for six months. Ann Clin Lab Sci.
50:99–106. 2020.PubMed/NCBI
|
